Yeh CN - Search Results

1

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study.

Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, Chen MH. Chiang NJ, et al. Among authors: yeh cn. Clin Cancer Res. 2022 Oct 3;28(19):4248-4257. doi: 10.1158/1078-0432.CCR-22-1152. Clin Cancer Res. 2022. PMID: 35849151 Free PMC article. Clinical Trial.

2

Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.

Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan Cooperative Oncology Group, National Health Research Institutes, Zhunan, Taiwan. Chen LT, et al. Ann Surg. 2012 Jan;255(1):8-17. doi: 10.1097/SLA.0b013e3182363ff9. Ann Surg. 2012. PMID: 22104564 Clinical Trial.

3

Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.

Chen MH, Lin KJ, Yang WL, Kao YW, Chen TW, Chao SC, Chang PM, Liu CY, Tzeng CH, Chao Y, Chen MH, Yeh CN, Huang CY. Chen MH, et al. Among authors: yeh cn. Cancer. 2013 Jan 15;119(2):293-303. doi: 10.1002/cncr.27743. Epub 2012 Jul 18. Cancer. 2013. PMID: 22810956 Free article.

4

Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.

Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Chen MH, et al. Among authors: yeh cn, yeh ts. Oncotarget. 2014 May 15;5(9):2372-89. doi: 10.18632/oncotarget.1706. Oncotarget. 2014. PMID: 24796583 Free PMC article.

5

Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.

Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN. Chen MH, et al. Among authors: yeh cn, yeh ts. Oncotarget. 2015 Sep 15;6(27):23594-608. doi: 10.18632/oncotarget.4335. Oncotarget. 2015. PMID: 26090720 Free PMC article.

6

MART-10, the new brand of 1α,25(OH)2D3 analog, is a potent anti-angiogenic agent in vivo and in vitro.

Chiang KC, Sun CC, Chen MH, Huang CY, Hsu JT, Yeh TS, Chen LW, Kuo SF, Juang HH, Takano M, Kittaka A, Chen TC, Yeh CN, Pang JH. Chiang KC, et al. Among authors: yeh cn, yeh ts. J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):26-34. doi: 10.1016/j.jsbmb.2015.09.022. Epub 2015 Sep 15. J Steroid Biochem Mol Biol. 2016. PMID: 26385607

7

ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.

Chen MH, Weng JJ, Cheng CT, Wu RC, Huang SC, Wu CE, Chung YH, Liu CY, Chang MH, Chen MH, Chiang KC, Yeh TS, Su Y, Yeh CN. Chen MH, et al. Among authors: yeh cn, yeh ts. Clin Cancer Res. 2016 Aug 15;22(16):4225-35. doi: 10.1158/1078-0432.CCR-15-1800. Epub 2016 Apr 13. Clin Cancer Res. 2016. PMID: 27076629

8

Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor.

Koo DH, Ryu MH, Kim KM, Yang HK, Sawaki A, Hirota S, Zheng J, Zhang B, Tzen CY, Yeh CN, Nishida T, Shen L, Chen LT, Kang YK. Koo DH, et al. Among authors: yeh cn. Cancer Res Treat. 2016 Oct;48(4):1155-1166. doi: 10.4143/crt.2016.187. Epub 2016 Jun 24. Cancer Res Treat. 2016. PMID: 27384163 Free PMC article.

9

A Prognostic Nomogram for Overall Survival of Patients After Hepatectomy for Intrahepatic Cholangiocarcinoma.

Yeh CN, Wang SY, Chen YY, Chen MH, Chiang KC, Cheng CT, Tsai CY, Wang CC, Yeh TS, Chen TC. Yeh CN, et al. Among authors: yeh ts. Anticancer Res. 2016 Aug;36(8):4249-58. Anticancer Res. 2016. PMID: 27466540

10

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models.

Lin SF, Lin JD, Hsueh C, Chou TC, Yeh CN, Chen MH, Wong RJ. Lin SF, et al. Among authors: yeh cn. Oncotarget. 2017 Jun 20;8(25):41294-41304. doi: 10.18632/oncotarget.17180. Oncotarget. 2017. PMID: 28476040 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

321 results

Search Page